Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure.
Year: 2016
Type: article
Abstract: Heart failure is a life-threatening condition that affects approximately 5.7 million individuals aged ≥20 years in the United States.1 With an estimated 870,000 new cases of heart failure occurring annually, heart failure is expected to affect more than 8 million people aged ≥18 years by 2030—an alarming 46% increase from 2012.1 And because heart failure increases in individuals aged ≥65 years, this disease will have a major impact in the coming decades as the aging US population increases steadily.1
Source: Europe PMC (PubMed Central)
Author: Loretta Fala
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2554066766